Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma | MicrobiomeTrials← Back to trialsNCT06876142
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
SUSPENDEDPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-09-15Est. Completion: 2033-01-01
Enrollment target: 54 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Extramedullary Disease in Multiple MyelomaMultiple Myeloma
This phase I/II trial tests the safety and effectiveness of extramedullary disease (EMD)-directed external beam radiatio…
Duarte, United StatesCompleted Jan 18, 2030
CardiotoxicityCancerCardiac ArrhythmiaLeft Ventricular DysfunctionBreast CancerMultiple Myeloma
This pilot study will evaluate the validity and feasibility of ambulatory cardiac monitoring to identify markers of card…
Minneapolis, United States
Est. completion Mar 1, 2028